logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Abilify MyCite (aripiprazole with sensor) for bipolar disorder and schizophrenia

< Back

Abilify MyCite (aripiprazole with sensor) for bipolar disorder and schizophrenia

Drugs

Mental Health, Drug Abuse and Learning Difficulties, Neurology and Neurosurgery

June 2020


Abilify MyCite (aripiprazole with sensor) is in clinical development for the treatment of adults with Bipolar Disorder (BP1) and Schizophrenia (SCH). BP1 is a mental health condition that causes high and low mood swings that go on for longer periods of time, compared to usual fluctuations in mood. SCH can result in a person having relapses into episodes of psychosis, which can include losing touch with reality through hallucinations and hearing voices. Anyone can develop these mental health conditions throughout their lifetime, however they are more common in young adults.

Abilify MyCite is a drug-device combination comprising aripiprazole embedded with an Ingestible Event Marker (IEM) sensor. The aripiprazole attaches in the brain to receptors which help normalise the activity of the brain. The drug is packaged within an innovative system which helps patients (and healthcare workers) monitor when the medication is taken through integration with a sensor patch and app. Abilify MyCite is different to other ways of monitoring whether medication has been taken because it gives results of the actual medication taken, without need for blood or urine samples, as opposed to an estimate and if licensed, will offer an additional treatment option for patients with BP1 and SCH.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts